$0.47
Market Capitalization | 8.2M |
Book Value | - $2.19 |
Earnings Per Share (EPS) | -1.49 |
Wall Street Target Price | 2.5 |
Profit Margin | -87.14% |
Operating Margin TTM | -63.92% |
Return On Assets TTM | -40.15% |
Return On Equity TTM | 0.0% |
Revenue TTM | 27.7M |
Revenue Per Share TTM | 1.71 |
Quarterly Revenue Growth YOY | 35.3% |
Gross Profit TTM | 7.3M |
EBITDA | -17.2M |
Diluted Eps TTM | -1.49 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.41 |
EPS Estimate Next Year | -1.1 |
EPS Estimate Current Quarter | -0.31 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 431.91%
FY20 | Y/Y Change | |
---|---|---|
Revenue | 8.3M | - |
Net Income | -6.2M | - |
Net Profit Margin | -74.5% | - |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 14.1M | ↑ 69.86% |
Net Income | -6.0M | ↓ 3.17% |
Net Profit Margin | -42.47% | ↑ 32.03% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 19.4M | ↑ 37.79% |
Net Income | 3.3M | ↓ 155.29% |
Net Profit Margin | 17.04% | ↑ 59.51% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 27.7M | ↑ 42.59% |
Net Income | -24.1M | ↓ 829.12% |
Net Profit Margin | -87.14% | ↓ 104.18% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 5.0M | ↑ 2.84% |
Net Income | -3.1M | ↑ 10.61% |
Net Profit Margin | -62.49% | ↓ 4.39% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 5.8M | ↑ 15.89% |
Net Income | 2.2M | ↓ 170.7% |
Net Profit Margin | 38.12% | ↑ 100.61% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.8M | ↑ 0.28% |
Net Income | -8.5M | ↓ 483.52% |
Net Profit Margin | -145.79% | ↓ 183.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.9M | ↑ 19.38% |
Net Income | 904.9K | ↓ 110.69% |
Net Profit Margin | 13.05% | ↑ 158.84% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.1M | ↑ 1.98% |
Net Income | -11.2M | ↓ 1341.95% |
Net Profit Margin | -158.93% | ↓ 171.98% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.8M | ↑ 10.84% |
Net Income | -6.9M | ↓ 38.88% |
Net Profit Margin | -87.63% | ↑ 71.3% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 6.4M | - |
Total Liabilities | 53.6M | - |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 7.6M | ↑ 20.12% |
Total Liabilities | 60.9M | ↑ 13.53% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 33.2M | ↑ 334.63% |
Total Liabilities | 53.7M | ↓ 11.78% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 26.3M | ↓ 20.81% |
Total Liabilities | 52.9M | ↓ 1.5% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 12.3M | ↑ 13.13% |
Total Liabilities | 74.8M | ↑ 7.11% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 33.2M | ↑ 170.88% |
Total Liabilities | 53.7M | ↓ 28.24% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 28.6M | ↓ 13.89% |
Total Liabilities | 55.7M | ↑ 3.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 25.2M | ↓ 11.76% |
Total Liabilities | 51.0M | ↓ 8.56% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 30.4M | ↑ 20.45% |
Total Liabilities | 63.8M | ↑ 25.07% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 26.3M | ↓ 13.48% |
Total Liabilities | 52.9M | ↓ 17.04% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -3.8M | - |
Investing Cash Flow | -85.4K | - |
Financing Cash Flow | 4.5M | - |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.6M | ↑ 22.47% |
Investing Cash Flow | -301.3K | ↑ 252.64% |
Financing Cash Flow | 4.9M | ↑ 9.51% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.2M | ↑ 120.91% |
Investing Cash Flow | -1.4M | ↑ 349.27% |
Financing Cash Flow | 26.0M | ↑ 432.82% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.5M | ↓ 19.14% |
Investing Cash Flow | -99.0K | - |
Financing Cash Flow | 2.6M | ↑ 79.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.5M | ↑ 271.24% |
Investing Cash Flow | -1.0M | ↑ 932.17% |
Financing Cash Flow | 20.3M | ↑ 688.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.1M | ↓ 43.54% |
Investing Cash Flow | -974.6K | ↓ 4.66% |
Financing Cash Flow | -288.9K | ↓ 101.43% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.7M | ↑ 51.88% |
Investing Cash Flow | -237.2K | ↓ 75.67% |
Financing Cash Flow | -450.8K | ↑ 56.06% |
Sell
Neutral
Buy
Prosomnus Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
Organization | Prosomnus Inc |
Employees | 136 |
CEO | Mr. Leonard Liptak |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$0.47
+0.0%
Keyarch Acquisition Corp
$0.47
+0.0%
Connexa Sports Technologies Inc
$0.47
+0.0%
Us Value Etf
$0.47
+0.0%
First Wave Biopharma Inc
$0.47
+0.0%
Global X Msci Next Emerging
$0.47
+0.0%
Fat Projects Acquisition Corp
$0.47
+0.0%
Capital Link Global Fintech
$0.47
+0.0%
Applied Uv Inc
$0.47
+0.0%